High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study

Gian Francesco Mureddu1,2, Cesare Greco1, Stefano Rosato3, Paola D’Errigo3, Leonardo De Luca2, Gabriella Badoni3, Pompilio Faggiano4,5, Fulvia Seccareccia3

 

The risk of recurrent events among survivors of acute myocar- dial infarction (AMI) is understudied. The aim of this analysis was to investigate the role of residual high thrombotic risk (HTR) as a predictor of recurrent in-hospital events after AMI. This retrospec- tive cohort study included 186,646 patients admitted with AMI from 2009 to 2010 in all Italian hospitals who were alive 30 days after the index event. HTR was defined as at least one of the fol- lowing in the 5 years preceding AMI: previous myocardial infarc- tion, ischemic stroke/other vascular disease, type 2 diabetes mel- litus, renal failure. Risk adjustment was performed in all multi- variate survival analyses. Rates of major cardiac and cerebrovas- cular events (MACCE) within the following 5 years were calcu- lated in both patients without fatal readmissions at 30 days and in those free from in-hospital MACCE at 1 year from the index hos

pitalization. The overall 5-year risk of MACCE was higher in patients with HTR than in those without HTR, in both survivors at 30 days [hazard ratio (HR), 1.49; 95% confidence interval (CI), 1.45-1.52; p<0.0001] and in those free from MACCE at 1 year (HR, 1.46; 95% CI, 1.41-1.51; p<0.0001). The risk of recurrent MACCE increased in the first 18 months after AMI (HR, 1.49) and then remained stable over 5 years. The risk of MACCE after an AMI endures over 5 years in patients with HTR. This is also true for patients who did not have any new cardiovascular event in the first year after an AMI. All patients with HTR should be iden- tified and addressed to intensive preventive care strategies